$Seattle Genetics(SGEN)$ Although the full commercial potential of Seattle Genetics'
ADC technology remains unknown, the firm has seen
dramatic results in the clinic. In trials, Adcetris--an anti-CD30
ADC--demonstrated a 75% response rate in patients with
relapsed/refractory Hodgkin's lymphoma. In contrast, a 2005
trial of SGN-30--an anti-CD30 naked monoclonal
antibody--failed to achieve any objective responses in the
same patient population, and several other non-ADC drug
candidates also have faltered in trials. Seattle Genetics'
early-stage pipeline contains several ADCs that seek to
address expansive markets like prostate and kidney cancer,
which we think positions the firm for solid long-term growth